(Q36100853)

12 August 2017

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform (English)

1 reference

12 August 2017

1 reference

1 reference

1 reference

1

David R Gandara

1 reference

12 August 2017

3

Carol Bult

1 reference

12 August 2017

Philip C Mack

2

1 reference

12 August 2017

Tianhong Li

4

1 reference

12 August 2017

Primo N Lara

5

1 reference

12 August 2017

Jonathan W Riess

6

1 reference

12 August 2017

Stephanie H Astrow

7

1 reference

12 August 2017

Regina Gandour-Edwards

8

1 reference

12 August 2017

David T Cooke

9

1 reference

12 August 2017

Ken Y Yoneda

10

1 reference

12 August 2017

Elizabeth H Moore

11

1 reference

12 August 2017

Chong-Xian Pan

12

1 reference

12 August 2017

Rebekah A Burich

13

1 reference

12 August 2017

Elizabeth A David

14

1 reference

12 August 2017

James G Keck

15

1 reference

12 August 2017

Susan Airhart

16

1 reference

12 August 2017

Neal Goodwin

17

1 reference

12 August 2017

Ralph W de Vere White

18

1 reference

12 August 2017

Edison T Liu

19

1 reference

12 August 2017

language of work or name

English

0 references

publication date

18 March 2015

1 reference

12 August 2017

1 reference

12 August 2017

16

1 reference

12 August 2017

3

1 reference

12 August 2017

165-172

1 reference

Adaptive resistance to targeted therapies in cancer

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Mouse Tumor Biology (MTB): a database of mouse models for human cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Patient-derived tumour xenografts as models for oncology drug development

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Drug development and clinical trials--the path to an approved cancer drug

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Reengineering translational science: the time is right

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Evolutionary dynamics of intratumor heterogeneity.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

How genetically engineered mouse tumor models provide insights into human cancers

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

How to improve R&D productivity: the pharmaceutical industry's grand challenge

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Humanized mice in translational biomedical research

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

New approaches to molecular cancer therapeutics

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Mouse modeling in oncologic preclinical and translational research

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

The use of targeted mouse models for preclinical testing of novel cancer therapeutics.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

The mighty mouse: genetically engineered mouse models in cancer drug development

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

High drug attrition rates--where are we going wrong?

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4586173

Genomics and the second golden era of cancer drug development

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25838158

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.CLLC.2015.03.001

1 reference

12 August 2017

1 reference

12 August 2017

1 reference